SU
SUPN.US Supernus Pharmaceuticals, Inc.
- Market cap
- USD 6.03B
- P/E
- -
- P/B
- 5.64x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SUPN.US undervalued?
Graham numberThe Graham number of Supernus Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Supernus Pharmaceuticals, Inc. fundamental analysis
No fundamental analysis for Supernus Pharmaceuticals, Inc. yet.
Supernus Pharmaceuticals, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Supernus Pharmaceuticals, Inc.
Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxon…
Full company profileSupernus Pharmaceuticals, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Supernus Pharmaceuticals, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 969M | 1.15B | 960M | 785M | 647M | 791M | 901M | 1.09B | 1.19B | 1.24B | 1.35B |
| Gross Profit | 858M | 1.03B | 825M | 645M | 550M | 664M | 750M | 919M | 957M | 993M | 1.17B |
| Operating Income | 338M | 423M | 317M | 178M | -156M | 213M | -81.0M | -156M | 32.0M | 265M | 637M |
| EBITDA | 150M | 206M | 311M | 230M | -123M | 238M | -46.0M | -99.0M | 83.0M | 304M | 635M |
| Net Income | 32.1M | 60.9M | 263M | 134M | -148M | 205M | -44.0M | -129M | 2.00M | 210M | 464M |
| EPS | 0.62 | 0.41 | 4.86 | 0.89 | -1.01 | 1.33 | -0.32 | -0.91 | 0.02 | 1.64 | 3.80 |
| Balance Sheet | |||||||||||
| Total Assets | 310M | 1.44B | 978M | 1.65B | 1.53B | 1.83B | 1.78B | 1.77B | 1.32B | 1.20B | 1.33B |
| Total Liabilities | 118M | 1.65B | 525M | 1.44B | 1.45B | 1.63B | 1.73B | 1.96B | 1.67B | 1.30B | 1.39B |
| Shareholders' Equity | 192M | -203M | 453M | 209M | 82.0M | 203M | 51.3M | -191M | -348M | -98.0M | -60.0M |
| Cash & Short-term Investments | 90.1M | 863M | 356M | 1.06B | 858M | 1.10B | 898M | 410M | 320M | 195M | 305M |
| Total Debt | 73.5M | 482M | 332M | 293M | 285M | 286M | 277M | 283M | 375M | 351M | 501M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 407M | 295M | 303M | 151M | -193M | 353M | -4.00M | -300M | 36.0M | -27.0M | 423M |
| Capital Expenditure | 35.0M | 43.0M | 41.0M | 7.00M | 4.00M | 34.0M | 5.00M | 53.0M | 31.0M | 67.0M | 54.7M |
| Free Cash Flow | 372M | 252M | 262M | 144M | -197M | 319M | -9.00M | -353M | 5.00M | -94.0M | 368M |
| Ratios | |||||||||||
| ROE | 16.7% | - | 58.0% | 64.1% | -180.5% | 101.0% | -85.8% | - | - | - | - |
| ROA | 10.4% | 4.2% | 26.9% | 8.1% | -9.7% | 11.2% | -2.5% | -7.3% | 0.2% | 17.4% | 34.8% |
| Net Profit Margin | 3.3% | 5.3% | 27.4% | 17.1% | -22.9% | 25.9% | -4.9% | -11.8% | 0.2% | 16.9% | 34.3% |
| Debt to Equity | 0.38x | - | 0.73x | 1.40x | 3.48x | 1.41x | 5.40x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Supernus Pharmaceuticals, Inc. dividends
Supernus Pharmaceuticals, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Oct 11, 2022.
Who owns Supernus Pharmaceuticals, Inc.
- Insiders 2.06%
- Institutions 61.24%
- Public & others 36.70%
- Shares outstanding 208M
- Free float 115M
Top funds holding SUPN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 3.49M | 6.08% | -0.14% | Oct 2026 |
| Nomura Small Cap Core I | 1.79M | 3.12% | -6.61% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.76M | 3.07% | +0.48% | Sep 2026 |
| iShares Russell 2000 ETF | 1.42M | 2.47% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.24M | 2.16% | -1.83% | Sep 2026 |
| Vanguard Explorer Inv | 870K | 1.51% | +9.89% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 809K | 1.41% | +0.41% | Sep 2026 |
| Fidelity Small Cap Index | 614K | 1.07% | +0.15% | Aug 2026 |
| Nuveen Quant Small Cap Equity R6 | 598K | 1.04% | +118.23% | Sep 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 530K | 0.92% | -0.05% | Oct 2026 |
| Loomis Sayles Small Cap Growth Instl | 527K | 0.92% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 486K | 0.85% | 0.00% | Oct 2026 |
| Vanguard Tax-Managed Small Cap Adm | 375K | 0.65% | 0.00% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 372K | 0.65% | +1.91% | Sep 2026 |
| International Biotechnology Ord | 368K | 0.64% | 0.00% | Sep 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 361K | 0.63% | -0.40% | Oct 2026 |
| Vanguard Russell 2000 ETF | 326K | 0.57% | +1.13% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 307K | 0.53% | +0.23% | Oct 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 282K | 0.49% | +200.54% | Oct 2026 |
| Invesco Pharmaceuticals ETF | 279K | 0.49% | +0.24% | Sep 2026 |
Top institutions holding SUPN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 9.35M | 16.27% | +6.28% | Jun 2026 |
| Westfield Capital Management Company, L.P. | 3.90M | 6.78% | +274.10% | Sep 2026 |
| Millennium Management LLC | 3.85M | 6.71% | +16.20% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 3.82M | 6.64% | +83.72% | Sep 2026 |
| Vanguard Portfolio Management, LLC | 3.31M | 5.75% | +2.06% | Jun 2026 |
| Armistice Capital, LLC | 2.65M | 4.61% | +39.62% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.52M | 4.38% | +2.01% | Jun 2026 |
| State Street Corp | 2.46M | 4.28% | +7.50% | Jun 2026 |
| Delaware Management Holdings Inc | 2.38M | 4.14% | +16.74% | Jun 2026 |
| Geode Capital Management, LLC | 1.57M | 2.73% | -3.29% | Jun 2026 |
| Stephens Inv Mgmt Group LLC | 1.49M | 2.59% | +9.95% | Jun 2026 |
| Renaissance Technologies Corp | 1.48M | 2.57% | -13.31% | Jun 2026 |
| Loomis, Sayles & Company LP | 1.48M | 2.57% | +3.47% | Jun 2026 |
| Citadel Advisors Llc | 1.37M | 2.39% | -8.00% | Jun 2026 |
| Two Sigma Investments LLC | 1.18M | 2.06% | +336.67% | Jun 2026 |
| LSV Asset Management | 1.14M | 1.99% | +11.38% | Sep 2026 |
| GW&K Investment Management, LLC | 1.04M | 1.81% | -1.70% | Jun 2026 |
| Sofinnova Ventures | 1.04M | 1.80% | +8.59% | Jun 2026 |
| Qube Research & Technologies | 922K | 1.61% | +85.10% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 877K | 1.53% | -4.05% | Jun 2026 |
Supernus Pharmaceuticals, Inc. company profile
- Company name
- Supernus Pharmaceuticals, Inc.
- Ticker
- SUPN.US
- Exchange
- USA Stocks
- Listed since
- May 1, 2012
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 827
- Fiscal year end
- December
- Address
- 9715 Key West Avenue, Rockville, MD, United States, 20850
- Phone
- 301 838 2500
- Website
- supernus.com
About Supernus Pharmaceuticals, Inc.
Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Supernus, Inc. was formerly known as Indivior Pharmaceuticals, Inc. and changed its name Supernus, Inc. in November 2026. Supernus, Inc. was incorporated in 2014 and is headquartered in Rockville, Maryland.
Supernus Pharmaceuticals, Inc. management
10- Dr. Christian HeidbrederChief Scientific Officer · born 1963
- Mr. Jack A. Khattar M.B.A.President, CEO & Director · born 1961
- Mr. Timothy C. DecSenior VP & CFO · born 1959
- Mr. Jason ThompsonVice President of Investor Relations
- Mr. Kevin L. EspinozaChief Integrity & Compliance Officer
- Ms. Angela Colon-Mahoney M.S.Chief Human Resources Officer · born 1976
- Ms. Vanessa ProcterExecutive Vice President of Corporate Affairs
- Dr. Ann Wheeler Pharm.D.Chief Medical Officer
- Mr. Ken MoriciSenior Vice President of Manufacturing & Supply
- Ms. Alice Grace GivensCompany Secretary · born 1973